T-cell therapy in the treatment of post-transplant lymphoproliferative disease

Nat Rev Clin Oncol. 2012 Sep;9(9):510-9. doi: 10.1038/nrclinonc.2012.111. Epub 2012 Jul 17.


Post-transplant lymphoproliferative diseases (PTLD) associated with Epstein-Barr virus (EBV) infection often develop after organ and haematopoietic stem-cell transplantation. These lymphoproliferative diseases are tumours that usually express all latent EBV viral proteins, and are therefore amenable to T-cell-based immune therapies, such as donor lymphocyte infusions and the adoptive transfer of EBV-specific cytotoxic T lymphocytes. In this Review, we describe current approaches of T-cell-based therapies to treat PTLD, and describe strategies that improve the feasibility of such treatment.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adoptive Transfer
  • Cell- and Tissue-Based Therapy
  • Epstein-Barr Virus Infections*
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Immunotherapy, Adoptive / methods*
  • Lymphoproliferative Disorders / drug therapy*
  • Lymphoproliferative Disorders / etiology
  • T-Lymphocytes, Cytotoxic*
  • Time Factors


  • Immunosuppressive Agents